Statins: where are we now?
Statin therapy reduces the risk of cardiac events by 30% in both primary and secondary prevention. Although fine-tuning of the evidence will occur as more clinical trials report, the challenge is now to implement the evidence to the benefit of patients.
Cowie
M R
MR
Aberdeen Royal Infirmary, Aberdeen AB25 2ZN.
D000368:Aged; D003327:Coronary Disease / Q000188:drug therapy* / Q000191:economics / Q000209:etiology; D003362:Cost-Benefit Analysis; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000188:drug therapy; D016527:Drug Costs; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000191:economics / Q000627:therapeutic use*; D008297:Male; D018579:Patient Selection; D019821:Simvastatin / Q000191:economics / Q000627:therapeutic use*; D016896:Treatment Outcome
D000960:Hypolipidemic Agents; D019821:Simvastatin